Volta Medical – a provider of artificial intelligence solutions that assist electrophysiologist physicians in treating complex cardiac arrhythmias such as atrial fibrillation (AF) – raised €36 million in new Series B funding.
Vensana Capital led the investment round with co-investment from Lightstone Ventures and existing investor Gilde Healthcare.
According to the company, the latest funding will help accelerate its new product development efforts, support additional clinical trials, prepare for full-scale US commercialization, and pursue further regulatory approvals for its AI companion decision-support software that guides physicians with identification and real-time annotation of unique abnormalities on 3D anatomical and electrical maps of the heart, ultimately leading to improving clinical outcomes for patients.
Including the latest Series B round, Volta Medical has raised over €70 million in funding to date. In January last year, the company raised over €23 million in equity funding from Gilde Healthcare and existing investor Pasteur Mutualité.
Commenting on the funding news, Theophile Mohr Durdez, Volta Medical CEO and co-founder, said: “There is a critical need to improve precision and consistency in cardiac ablation procedures for patients with persistent AF.” “With half of these patients requiring repeat treatments, clinicians need tools that enable them to better understand the disease and drastically improve patient outcomes. We believe VOLTA’s VX1 has the potential to do just that in a consistent, reproducible way. We are most grateful to the teams at Vensana, Lightstone, and Gilde for their support and confidence as we partner to further validate our products and expand access to it globally.”
Investors
Vensana Capital, a venture capital firm that invests in healthcare with innovations in medical technology startups, has invested more than $500 million in digital health companies to date. The firm’s investment portfolio includes – Apella $21 million, Cleerly $235 million, Moxe Health $30 million, and Personal Genome Diagnostics (PGDx) $103 million.
“Volta Medical’s technology is designed to redefine how electrophysiologists make real-time decisions in pinpointing areas relevant to atrial fibrillation persistence,” said Justin Klein, co-founder and managing partner of Vensana Capital. “We applaud the team’s commitment to validating their products with an investment in multiple high-quality clinical trials. We are confident that Volta’s innovative AI software will transform the effectiveness and efficiency of these challenging procedures.”
According to our database, clinical decision support software startups have raised close to $15 billion in funding to date.
The latest funding round in this space includes:
CathVision, a provider of AI-guided electrophysiology solutions designed to enhance clinical decision-making in cardiac ablation operations, secured $7.2 million in equity funding from existing investors.
Corti.ai, a voice-enabled digital clinical decision support assistant for medical professionals, raised $27 million in Series A funding. Vaekstfonden – The Danish Growth Fund and Chr led the investment round with participation from Augustinus Fabrik, Hearcore, Id Invest, and byFounders.
